Fig. 3From: 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity studyPre-treatment and post-treatment measures a FDG SUVmax b FLT SUVmax shown as days on AI therapyBack to article page